Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240470 | 1.00 | MAPK10 (0.47) | MAPK10TSHRKCNH2PARP1CTSL | |
| SCHEMBL1876605 | 0.80 | ALDH1A1 (0.41) | RAB9AMAPTNPC1POLBALDH1A1 | |
| SCHEMBL8234794 | 0.80 | ALDH1A1 (0.41) | RAB9AMAPTNPC1POLBALDH1A1 | |
| SCHEMBL1876606 | 0.80 | ALDH1A1 (0.41) | RAB9AMAPTNPC1POLBALDH1A1 | |
| SCHEMBL12671959 | 0.79 | PARP1 (0.52) | PARP1CTSLCTSBCES2CES1 | |
| SCHEMBL11410237 | 0.72 | TSHR (0.47) | MAPK10TSHRKCNH2RAB9AHDAC1 | |
| SCHEMBL11410241 | 0.72 | TSHR (0.47) | MAPK10TSHRKCNH2RAB9AHDAC1 | |
| SCHEMBL11416679 | 0.72 | MAPK10 (0.46) | MAPK10TSHRKCNH2TP53MEN1 | |
| SCHEMBL8308827 | 0.71 | GABRA1 (0.44) | TSHRRAB9AMAPTNPC1POLB | |
| SCHEMBL8308825 | 0.71 | GABRA1 (0.44) | TSHRRAB9AMAPTNPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105496-A1 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds | GILEAD COLORADO, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090306373-A1 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-1965796-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Gilead Colorado, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1962840-A1 | USE OF 4, 7-DIHYDROTHIENO [2, 3-B]PYRIDINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Gilead Colorado, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076379-A2 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | GILEAD COLORADO, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073555-A1 | USE OF 4, 7-DIHYDROTHIENO [2, 3-B] PYRIDINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR DISEASES | GILEAD COLORADO, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306373-A1 | 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | MYH2, TNNT2, MYLK2 | MAPK10 1390/4885TSHR 4340/4885KCNH2 481/4885 |
| US-20110105496-A1 | Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds | MYH2, MYLK2, TNNI3 | MAPK10 2710/4885TSHR 4190/4885KCNH2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.